[Skip to Content]
[Skip to Content Landing]
Article
October 1988

Topical Ciprofloxacin Treatment of Pseudomonas Keratitis in Rabbits

Author Affiliations

From The Wilmer Ophthalmological Institute (Drs O'Brien, Sawusch, and Gottsch) and Department of Laboratory Medicine (Dr Dick), The Johns Hopkins Hospital, Baltimore.

Arch Ophthalmol. 1988;106(10):1444-1446. doi:10.1001/archopht.1988.01060140608032
Abstract

• Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa. A rabbit model of bacterial keratitis was used to assess the in vivo efficacy of topical ciprofloxacin. Albino rabbits received intrastromal injections of 5 × 102 aminoglycoside-resistant P aeruginosa organisms. At five hours after inoculation, ciprofloxacin (3 mg/mL) therapy was initiated (one drop every 30 minutes for 12 hours). Corneal tissue was then excised for bacterial colony counts. No organisms were recovered from ciprofloxacin-treated eyes, compared with an average of 3.1 × 107 organisms per milliliter recovered from untreated controls. This model suggests that topical ciprofloxacin may be clinically useful in the treatment of aminoglycoside-resistant P aeruginosa keratitis.

×